MetaCap

Who Owns Lyell Immunopharma Stock?

NASDAQ: LYELHealth CareBiotechnology: Pharmaceutical PreparationsUSD

13.80+0.22 (+1.62%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Ownership breakdown

Held by institutions
49.27%
Institutional holders
144
  • Institutions 49.3%
  • Insiders 28.6%
  • Public and other 22.1%

Who owns Lyell Immunopharma stock?

Institutional investors own about 49.3% of Lyell Immunopharma's shares, spread across 144 institutions that file 13F reports. That level of institutional ownership is moderate. Insiders, including executives, directors and large founding shareholders, hold 28.62% of LYEL.

The largest institutional holders are Arch Venture Management, Llc (10.14%), GSK plc (4.72%) and Blackrock Inc. (2.50%). Together, the top 10 institutions control 29.3% of shares outstanding. In their latest filings, 3 of the top 10 institutions increased their LYEL positions and 2 reduced them.

Summary generated from market data by MetaCap's automated system. Methodology

Top institutional holders of LYEL

Lyell Immunopharma top institutional holders
InstitutionShares% HeldChange
Arch Venture Management, Llc3.25M10.14%0.0%
GSK plc1.51M4.72%0.0%
Blackrock Inc.799.06K2.50%+10.3%
Orland Properties Ltd.754.70K2.36%0.0%
Vanguard Capital Management LLC748.85K2.34%-4.8%
Decheng Capital LLC692.05K2.16%0.0%
Almitas Capital LLC581.41K1.82%+0.6%
Millennium Management Llc367.47K1.15%-19.9%
AQR Capital Management, LLC345.92K1.08%+100.0%
venBio Partners LLC337.70K1.05%0.0%

% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.

Top mutual fund and ETF holders of LYEL

Lyell Immunopharma top fund holders
FundShares% Held
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund604.46K1.89%
iShares Trust-iShares Russell 2000 ETF228.11K0.71%
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund163.75K0.51%
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund107.31K0.34%
iShares Trust-iShares Russell 2000 Value ETF76.88K0.24%
SCHWAB STRATEGIC TRUST-Schwab U.S. Small-Cap ETF66.83K0.21%
iShares Trust-iShares Biotechnology ETF59.77K0.19%
VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund54.00K0.17%
Fidelity Concord Street Trust-Fidelity Extended Market Index Fund51.43K0.16%
VANGUARD WORLD FUND-Vanguard Health Care Index Fund28.49K0.09%

Frequently asked questions

Who is the largest shareholder of Lyell Immunopharma?

Arch Venture Management, Llc is the largest institutional shareholder of LYEL, owning 10.14% of shares outstanding (3.25M shares) as of its latest 13F filing.

What percentage of Lyell Immunopharma is owned by institutions?

Institutions own about 49.3% of LYEL shares and 69.0% of the public float.

How much of Lyell Immunopharma do insiders own?

Insiders, such as officers and directors, own about 28.62% of LYEL shares outstanding.

Where does institutional ownership data come from?

Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.

Related